Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.
Novo Nordisk, the pharmaceutical company behind Ozempic, has launched a national campaign promoting its injectable ...
Patients using Novo Nordisk’s NVO NONOF obesity treatment, Wegovy, have reportedly maintained an average weight loss of 10% over a four-year period, as per data revealed by the company on Tuesday.
Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are ...
Investors interested in the pharmaceutical industry are currently excited about the anti-obesity market. Weight-loss ...
FAT jabs could be the cancer hope of the future after early studies found they reduce the risk of tumours. The world’s top ...
Several promising drugs in phase 2 testing and beyond seek to offer patients a more convenient alternative to already popular ...
While Novo Nordisk charges $1,349 a month for Wegovy in the U.S., the drug costs just $140 a month in Germany and $92 a month in the U.K. Novo Nordisk has blamed middlemen in the U.S. healthcare ...
As chronic kidney disease rises nationwide, a new study partially conducted in Orlando suggests weight loss drugs like ...
Now that’s more like it. After investors frowned on Structure Therapeutics’ oral GLP-1 data in December 2023, the biotech is ...